Search research articles
Contact Us
Filters
Showing results (261-270 of 335) with videos related to
Page
of 34
Sort By:
Lancet (London, England)
|
September 7, 2012
Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial
Edoardo Camenzind, William Wijns, Laura Mauri, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|
May 5, 2012
European Registry of Carotid Artery Stenting: results from a prospective registry of eight high volume EUROPEAN institutions
Eugenio Stabile, Pallav Garg, Alberto Cremonesi, et al.
Circulation. Cardiovascular Interventions
|
November 3, 2016
Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update
Dominick J Angiolillo, Shaun G Goodman, Deepak L Bhatt, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
April 24, 2019
Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-Analysis
Thomas A Mavrakanas, Yiannis S Chatzizisis, Karim Gariani, et al.
Circulation
|
December 21, 2018
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update
Dominick J Angiolillo, Shaun G Goodman, Deepak L Bhatt, et al.
Circulation
|
May 2, 2007
Clinical end points in coronary stent trials: a case for standardized definitions
Donald E Cutlip, Stephan Windecker, Roxana Mehran, et al.
Archives of Internal Medicine
|
July 11, 2012
Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice
Amit P Amin, John A Spertus, David J Cohen, et al.
Kardiologia Polska
|
December 19, 2017
[2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.]
Marco Valgimigli, Héctor Bueno, Robert A Byrne, et al.
JACC. Cardiovascular Interventions
|
February 5, 2010
Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)
Martin B Leon, David E Kandzari, Eric L Eisenstein, et al.
Journal of the American College of Cardiology
|
March 20, 2015
Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction
Robert W Yeh, Dean J Kereiakes, Philippe Gabriel Steg, et al.
Page
of 34
Search research articles
Search
Showing results (261-270 of 335) with videos related to
Sort By:
Page
of 34
Lancet (London, England)
|
September 7, 2012
Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial
Edoardo Camenzind, William Wijns, Laura Mauri, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|
May 5, 2012
European Registry of Carotid Artery Stenting: results from a prospective registry of eight high volume EUROPEAN institutions
Eugenio Stabile, Pallav Garg, Alberto Cremonesi, et al.
Circulation. Cardiovascular Interventions
|
November 3, 2016
Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update
Dominick J Angiolillo, Shaun G Goodman, Deepak L Bhatt, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
April 24, 2019
Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-Analysis
Thomas A Mavrakanas, Yiannis S Chatzizisis, Karim Gariani, et al.
Circulation
|
December 21, 2018
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update
Dominick J Angiolillo, Shaun G Goodman, Deepak L Bhatt, et al.
Circulation
|
May 2, 2007
Clinical end points in coronary stent trials: a case for standardized definitions
Donald E Cutlip, Stephan Windecker, Roxana Mehran, et al.
Archives of Internal Medicine
|
July 11, 2012
Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice
Amit P Amin, John A Spertus, David J Cohen, et al.
Kardiologia Polska
|
December 19, 2017
[2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.]
Marco Valgimigli, Héctor Bueno, Robert A Byrne, et al.
JACC. Cardiovascular Interventions
|
February 5, 2010
Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)
Martin B Leon, David E Kandzari, Eric L Eisenstein, et al.
Journal of the American College of Cardiology
|
March 20, 2015
Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction
Robert W Yeh, Dean J Kereiakes, Philippe Gabriel Steg, et al.
Page
of 34